Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline and Vitamin E with SABR for Recurrent or New Primary NSCLC
NCT01871454Phase 2Recruiting
- Sponsor
- University of Louisville
- Start
- Oct 2013
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentoxifylline in non-small cell lung cancer (NSCLC), sponsored by University of Louisville. Primary endpoint: Overall treatment-related toxicity at 36 months. Started Oct 2013; status: recruiting.
02
Drugs
pentoxifylline
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01871454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871454.